Nathan M Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma, Doris S Kim, Mark R Lackner
{"title":"选择性WEE1抑制剂Azenosertib在临床前模型中与KRASG12C抑制剂显示协同抗肿瘤活性","authors":"Nathan M Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma, Doris S Kim, Mark R Lackner","doi":"10.1158/2767-9764.CRC-24-0411","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"240-252"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795354/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.\",\"authors\":\"Nathan M Jameson, Daehwan Kim, Catherine Lee, Blake Skrable, Alexandra Shea, Xiao Guo, Hooman Izadi, Mona Abed, Olivier Harismendy, Jianhui Ma, Doris S Kim, Mark R Lackner\",\"doi\":\"10.1158/2767-9764.CRC-24-0411\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Significance: </strong>Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.</p>\",\"PeriodicalId\":72516,\"journal\":{\"name\":\"Cancer research communications\",\"volume\":\" \",\"pages\":\"240-252\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795354/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2767-9764.CRC-24-0411\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0411","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.
Significance: Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
